Published • loading... • Updated
Clear Street starts Q32 Bio at buy; PT $38 - BioTuesdays
Summary by biotuesdays.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Clear Street starts Q32 Bio at buy; PT $38 - BioTuesdays
Clear Street initiated coverage of Q32 Bio (NASDAQ: QTTB) with a “buy” rating and price target of $38.00. The stock closed at $8.77 on September 25. Q32 Bio is a clinical-stage biotechnology company developing therapies designed to restore immune regulation across autoimmune and inflammatory diseases. Its lead program, bempikibart, is a fully human anti-IL-7Rα antibody […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
